Ignite Creation Date:
2024-05-06 @ 3:17 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04582188
Status:
UNKNOWN
Last Update Posted:
2020-11-06
First Post:
2020-10-04
Brief Title:
The Early Coagulopathy for the Prognosis in Sepsis
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
An Observational Study on the Prognostic Function of Early Coagulopathy in Sepsis Patients
Status:
UNKNOWN
Status Verified Date:
2020-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this cohort study the parameters TM TAT PIC tPAIC et al associated with the hemostatic system will be collected in sepsis patients when admitted to the Intensive Critical Unit Parameters will be evaluated for their prognostic function of 28 days mortality
Detailed Description:
The object of this study is to find the early mortality prognostic biomarkers within the hemostatic system in sepsis patients Blood samples will be collected from sepsis patients at admission Parameters reflect endothelial injury such as thrombomodulin TM tissue type plasminogen activator inhibitor complex tPAIC parameters reflect procoagulation condition such as thrombin-antithrombin complex TAT and parameters reflect hyperfibrinolysis such as plasmin-plasmin inhibitor complex PIC will be tested Based on the results of these parameters sepsis patients will be divided into coagulation parameter normal or abnormal groups Twenty-eight days of mortality will be determined by patient follow-up Regression analysis will be used to evaluate the relationship between these parameters and the mortality of sepsis patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None